addition to Wockhardt's development and finished dosage form capabilities, we
boast a state-of-the-art cGMP compliant API manufacturing facility approved by
the USFDA and UKMHRA.
Key Manufacturing Capabilities & Attributes:
- State-of-the-art facility to manufacture sterile cephalosporins
- Flexibility to manufacture high value - low volume products and
high volume products
- Multipurpose plant which can manufacture several
products at a time handling high pressure, high temperature (up to 250 degrees
Celsius) and low temperature (up to -70 degrees Celsius) reactions
- DMF's filed during last three years is 30+
developed in last three years is 50+
Key Research Capabilities
- R&D team consisting 70+ scientists of which 20+
scientists are PhD's
- API R&D team is supported by a dedicated analytical
group comprising 40 scientists, of which 5 are Ph.Ds.
- 30 years of API
process research experience
- Excellent History of precise and timely implementation
- Development of solutions to generate robust API processes.
- Equilibrium between low cost and high value added work
developed to date is 150+